Plain-English translation of NCT06272214 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether patients with advanced esophageal squamous cell carcinoma should receive radiation therapy after surgery if their cancer didn't completely disappear with chemotherapy and immunotherapy. Half of patients will receive radiation therapy along with ongoing immunotherapy (PD-1/PD-L1 inhibitors), while the other half will receive only the immunotherapy and careful monitoring. The trial wants to see whether the additional radiation therapy helps keep the cancer from coming back.
Some patients with advanced esophageal cancer don't have a complete response to chemotherapy and immunotherapy before surgery, meaning some cancer cells may remain. Doctors want to know if adding radiation therapy after surgery can lower the risk that the cancer will recur and improve long-term survival for these patients.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to one of two groups. Both groups receive immunotherapy injections every 3 weeks for up to 1 year after surgery. The radiation group will also receive radiation therapy 4–6 weeks after surgery, completed within 8 weeks, with daily outpatient visits for 5 weeks. You'll have follow-up visits every 3–4 months for the first 3 years, then every 6 months for 2 years, then annually. Researchers will track whether your cancer comes back and how well you survive over time.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China